Evidence map›Paper›PMID 40525806›Full record

ArticleACS infectious diseases2025

Single-Sample Melt-Based Screening for Rifampicin Susceptibility in the Emerging Mutation Hotspot at

Nicole A Malofsky, Swayashreyee B Dhungel, Megan E Pask, Frederick R Haselton

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nicole A MalofskyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0009-0002-2590-5319
Swayashreyee B DhungelDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
Megan E PaskDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
Frederick R HaseltonDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0000-0003-4282-5222

Funding

Point-of-Care RT-PCR System to Inform COVID-19 and Respiratory Illness DecisionsR01AI157827 · NIAID · VANDERBILT UNIVERSITY · PI Frederick R Haselton, Jonathan E Schmitz · 2020 to 2026
$4.7M
A 100-fold more sensitive TB diagnostic based on magnetic concentration and "coffee ring" formationR01AI135937 · NIAID · VANDERBILT UNIVERSITY · PI BLACKBURN, JONATHAN MICHAEL, HASELTON, FREDERICK R · 2017 to 2021
$1.7M
Urine TB diagnostic by amplicon reconstruction for PCR detection of DNA fragmentsR21AI152497 · NIAID · VANDERBILT UNIVERSITY · PI HASELTON, FREDERICK R · 2021 to 2022
$428k
NIAID NIH HHS R01 AI135937NIAID NIH HHS R01 AI157827NIAID NIH HHS R21 AI152497
6 · The paper itself

Abstract

Based on sequencing data, mutations at

Indexed as

Antitubercular AgentsBacterial ProteinsDNA-Directed RNA PolymerasesDrug Resistance, BacterialMycobacterium tuberculosisRifampinCodonHumansMicrobial Sensitivity TestsMutationAntitubercular AgentsBacterial ProteinsCodonDNA-Directed RNA PolymerasesRifampinrpoB protein, Mycobacterium tuberculosisemerging hotspotL-DNAmelt analysismutation screeningrifampicin resistancetuberculosis

Identifiers

PMID40525806
PMCPMC12261315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.